These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25484390)

  • 61. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.
    Hartmann JT; Kanz L
    Arch Dermatol; 2008 Nov; 144(11):1525-6. PubMed ID: 19015436
    [No Abstract]   [Full Text] [Related]  

  • 63. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Reilly LM; Gerami P; Guitart J
    Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
    Rosenbaum SE; Wu S; Newman MA; West DP; Kuzel T; Lacouture ME
    Support Care Cancer; 2008 Jun; 16(6):557-66. PubMed ID: 18274784
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
    Moss KG; Toner GC; Cherrington JM; Mendel DB; Laird AD
    J Pharmacol Exp Ther; 2003 Nov; 307(2):476-80. PubMed ID: 12966161
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy.
    Gordon KB; Tajuddin A; Guitart J; Kuzel TM; Eramo LR; VonRoenn J
    Cancer; 1995 Apr; 75(8):2169-73. PubMed ID: 7697608
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Expression of c-kit ligand in human keratinocytes.
    Morita E; Lee DG; Sugiyama M; Yamamoto S
    Arch Dermatol Res; 1994; 286(5):273-7. PubMed ID: 7520225
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Concurrent hand-foot skin reaction and hair depigmentation with sunitinib: report of a case and literature review of kinase inhibitors and blocking antibodies.
    Bansal S; Sardana K; Singh K; Garg VK
    Indian J Dermatol; 2014 Nov; 59(6):588-91. PubMed ID: 25484390
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).
    Anderson R; Jatoi A; Robert C; Wood LS; Keating KN; Lacouture ME
    Oncologist; 2009 Mar; 14(3):291-302. PubMed ID: 19276294
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
    Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Bednaríková D; Kocák I
    Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
    Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
    Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.